Clinicopathological variables

Number of patients, N

HER2, n (%)

P^*

Negative

Positive

Family history

No

97

61 (88.4)

8 (11.6)

0.9

Yes

10

16 (88.9)

2 (11.1)

Menopausal status

Premenopausal

124

79 (56.4)

22 (68.8)

0.2

Postmenopausal

85

61 (43.6)

10 (31.3)

Histological  type

IDC

175

119 (85)

23 (71.9)

0.5

ILC

19

13 (9.3)

4 (12.5)

Medullary

2

0

0

Papillary

3

2 (1.4)

1 (3.1)

Tubular

0

0

0

Mucinous

4

2 (1.4)

2 (6.3)

Mixed

6

4 (2.9)

2 (6.3)

Histological grade

Grade 1

6

6 (4.4)

0

0.05

Grade 2

105

62 (45.9)

20 (66.7)

Grade 3

90

67 (49.6)

10 (33.3)

Clinical stage

Stage 1

11

7 (5.1)

2 (6.3)

0.9

Stage 2

93

62 (44.9)

15 (46.9)

Stage 3

79

50 (36.2)

11 (34.4)

Stage 4

24

19 (13.8)

4 (12.5)

T

T1

21

16 (12)

2 (6.5)

0.4

T2

122

78 (58.6)

18 (58.1)

T3

40

30 (22.6)

6 (19.4)

T4

18

9 (6.8)

5 (16.1)

N

N0

61

44 (33.1)

11 (35.5)

0.7

N1

74

49 (36.8)

10 (32.3)

N2

55

34 (25.6)

7 (22.6)

N3

11

6 (4.5)

3 (9.7)

Number of positive lymph nodes

Negative

61

44 (33.1)

11 (35.5)

0.8

Positive

140

89 (66.9)

20 (64.5)

Metastases

M0

182

118 (86.1)

28 (87.5)

0.8

M1

24

19 (13.9)

4 (12.5)

Metastatic location

Bone

24

17 (33.3)

4 (28.6)

0.71

Liver

4

3 (5.9)

0

Lung

13

7 (13.7)

2 (14.3)

Multi-organ

33

21 (41.2)

6 (42.9)

Local recurrence

4

3 (5.9)

2 (14.3)

Recurrence [local or distant]

Yes

60

89 (63.6)

17 (53.1)

0.4

No

130

36 (25.7)

12 (37.5)

Metastasis at diagnosis

19

15 (10.7)

3 (9.4)

Status at last follow-up

Death

42

27 (19.3)

11 (34.4)

0.09

Free

134

90 (64.3)

19 (59.4)

Mets

33

23 (16.4)

2 (6.3)